In This Article:
Pharming (PHAR) Group announced overnight that the National Institute for Health and Care Excellence has issued positive final guidance recommending Joenja for reimbursement and use within the National Health Service in England and Wales for the treatment of activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older. The company says Joenja is now available for use and funded in England through the Innovative Medicines Fund. In Wales, Joenja is expected to be funded within the next three months through the NHS in specialist centers.
Stay Ahead of the Market:
-
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
-
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHAR: